Clinical trials: Neuroectodermal Tumors, Primitive
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Trial name
- NCT03126916
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 164 sites in United States, Canada and 1 more
- Volunteers
- 750 people
- Sponsor
- Children's Oncology Group
Sarcoma
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00020566
- Testing
- dactinomycin, busulfan, doxorubicin hydrochloride
- Where
- 103 sites in United States, Australia and 3 more
- Volunteers
- 1,200 people
- Sponsor
- University of Leicester
Sarcoma
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Phase II trial to study the effectiveness of topotecan in treating children who have recurrent, relapsed, or refractory sarcoma.
- Trial name
- NCT00003745
- Testing
- topotecan hydrochloride
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 125 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00360854
- Testing
- erlotinib hydrochloride, mutation analysis, polymorphism analysis
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Children's Cancer and Leukaemia Group
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)
Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma
This clinical trial studies genetic biomarkers from saliva samples in patients with Ewing sarcoma. Studying samples of saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in…
- Trial name
- NCT01876303
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- United States
- Volunteers
- 1,650 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Neuroblastoma
Prospective Multicenter Study of the Genomic, Transcriptomic, and Biological Profile of Patients With Neuroblastoma
This is an investigator-initiated, multicenter, prospective, non-profit study. Patients who provide informed consent to participate will be asked to provide a peripheral blood sample, a fresh tumor tissue sample (obtained by…
- Trial name
- PREME (NCT07881172)
- Where
- 35 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Giannina Gaslini
Neuroblastoma
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
- Trial name
- NCT06450041
- Testing
- Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 62 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Glioblastoma, Sarcoma
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression.
- Conditions
- Glioblastoma, Sarcoma, Neuroblastoma
- Trial name
- NCT01174537
- Testing
- New Castle Disease Virus
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Refractory Neuroblastoma, Soft Tissue Cancer
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft…
- Trial name
- NICE (NCT06438614)
- Testing
- HITS, Naxitamab + GM-CSF cycles, NICE
- Where
- Spain
- Volunteers
- 47 people
- Sponsor
- Fundació Sant Joan de Déu
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Neuroblastoma
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
The purpose of this study is to find out if "humanized 3F8" (Hu3F8) is safe for treating neuroblastoma and other cancers. A phase 1 study means the investigators are trying to find out what side effects happen when higher and…
- Trial name
- NCT01419834
- Testing
- Humanized 3F8 Monoclonal Antibody (Hu3F8)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendrocrine Tumors, Meningioma
Dosimetry Guided PRRT With 90Y-DOTATOC
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendrocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03013387
- Testing
- 90Y-DOTA-3-tyr-Octreotide, Positron Emission Tomography (PET) whole body scan, Amino Acids
- Sponsor
- Sue O'Dorisio
Recurrent Neuroblastoma
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma
Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients experience further progression.
- Trial name
- METRO-NB2012 (NCT02641314)
- Testing
- metronomic therapy
- Where
- 8 sites in Germany
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Medulloblastoma, Childhood
Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children
The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.
- Trial name
- NCT05406947
- Testing
- Prospective observational study, no intervention
- Volunteers
- 350 people
- Sponsor
- Beijing Tiantan Hospital
Sarcoma
Biomarker in Tissue Samples From Patients With Ewing Sarcoma
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01365949
- Testing
- microarray analysis, protein analysis, immunohistochemistry staining method
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Biomarkers in Young Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01169376
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Volunteers
- 380 people
- Sponsor
- Children's Oncology Group
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
This phase I trial is studying the side effects and best dose of pyrazoloacridine given together with peripheral stem cell or bone marrow transplantation in treating young patients with high-risk neuroblastoma.
- Trial name
- NCT00053950
- Testing
- pyrazoloacridine, filgrastim, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either…
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Synovial Sarcoma
- Trial name
- NCT00331643
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Nephroblastoma
Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings.
- Conditions
- Neuroblastoma, Nephroblastoma, Hepatoblastoma
- Trial name
- PsyRareCare (NCT05245123)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf